![(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二[4-(三氟甲基)苯基]-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[4-(trifluoromethyl)phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)](https://img.nicebiochem.com/20250502/89f20c8981610e19156414693f4e35e9bbcfb53340c3e8864505e2df67fc248b.png)
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二[4-(三氟甲基)苯基]-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[4-(trifluoromethyl)phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二-1-芘基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-1-pyrenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0446 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双(三苯基)-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis(triphenylsilyl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98%, (99% ee)
ZMR-15-0821 | 50mg
-
(11bS)-2,6-二(4-氯苯基)-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,1-d:1',2'-f]的[1,3,2]二氧磷杂七环 (11bS)-2,6-Bis(4-chlorophenyl)-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0386 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双(4-硝基苯基)-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis(4-nitrophenyl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0416 | 50mg
-
(11bS)-2,6-双[4-(2-萘基)苯基]-8,9,10,11,12,13,14,15-八氢-4-羟基-4-氧化物-二萘并[2,11-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-2,6-Bis[4-(2-naphthalenyl)phenyl]-8,9,10,11,12,13,14,15-octahydro-4-hydroxy-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0390 | 50mg
-
(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-双(4-甲氧基苯基)-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis(4-methoxyphenyl)-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0412 | 50mg
-
(11bR)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二-1-芘基-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环 (11bR)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-di-1-pyrenyl-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
ZMR-15-0444 | 50mg
中文名称：(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二[4-(三氟甲基)苯基]-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
英文名称：(11bS)-8,9,10,11,12,13,14,15-Octahydro-4-hydroxy-2,6-bis[4-(trifluoromethyl)phenyl]-4-oxide-dinaphtho[2,1-d:1',2'-f][1,3,2]dioxaphosphepin, 98% (99% ee)
分子式：C34H27F6O4P；分子量：644.5。
您正在浏览的产品：(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二[4-(三氟甲基)苯基]-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
手机版：(11bS)-8,9,10,11,12,13,14,15-八氢-4-羟基-2,6-二[4-(三氟甲基)苯基]-4-氧化物-二萘并[2,1-d:1',2'-f][1,3,2]二氧磷杂七环
本公司销售的所有产品仅供实验科研使用，不用于人体及临床诊断。
2. 色谱条件：C18色谱柱，梯度洗脱程序
3. 质谱条件：电喷雾离子源（ESI），负离子模式扫描
2. 三氟甲基基团可能产生同位素干扰峰，需通过质谱分辨率设置消除
以上信息仅供参考，请以相应标准的原文为准！